Obtenga las últimas noticias sobre las acciones de Evaxion con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de EVAX

Últimas noticias sobre

EVAXION A/S

Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MLGO

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

Long Ideas

AREN

CSTM

GDYN

GEAR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: CSTM, VIRX, EVAX, AREN y GDYN.

5 acciones en el foco este viernes: CSTM, VIRX, EVAX, AREN y GDYN

Evaxion AS

Press Releases

Evaxion announces business update and first quarter 2025 financial results

Evaxion receives grant funding to design new polio vaccine

Biotech

General

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Financing

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Small Cap

Opinion

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion announces business update and second quarter 2025 financial results

Evaxion to present at several conferences during the second half of 2025

AGEN

CELC

LYEL

ONCY

TSX:ONC

Abpro Hldgs

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Ainos

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Edesa Biotech

Evaxion

Geovax Labs

iBio

Imunon

Longeveron

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Lisata Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Nanoviricides

NextCure

BiomX

Q32 Bio

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Synlogic

Tharimmune

HC Wainwright & Co.

Lake Street

Ladenburg Thalmann

Oppenheimer

Comments

Evaxion Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL